<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04076865</url>
  </required_header>
  <id_info>
    <org_study_id>N-20190043</org_study_id>
    <nct_id>NCT04076865</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect Induced by Repeated Administration of Topical Local Anaesthetic (EMLA) on Itch</brief_title>
  <official_title>A Mechanistic Evaluation of the Nociceptive Desensitization Induced by Repeated Administration of Topical Local Anaesthetic Mixture of Lidocaine and Prilocaine (EMLA) in a Model of Histaminergic and Non-histaminergic Itch.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this experiment, the investigators would like to study if the repeated application of&#xD;
      local cuaneous anaesthetic EMLA cream will reduce itch induced by small needles from the&#xD;
      plant mucuna pruriens (also known as cowhage) and histamine (an itch proving substance formed&#xD;
      in the body).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The participant are blind about the location of EMLA and placebo application</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Superficial blood perfusion</measure>
    <time_frame>Change from baseline, up to three days after the first session</time_frame>
    <description>is measured by a Speckle contrast imager (FLPI, Moor Instruments, England).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Warm Detection Thresholds and Heat Pain Thresholds</measure>
    <time_frame>Change from baseline, up to three days after the first session</time_frame>
    <description>The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain to Supra-threshold Heat Stimuli</measure>
    <time_frame>Change from baseline, up to three days after the first session</time_frame>
    <description>The tests for thermal sensation will all be performed using a PATHWAY ATS (Medoc Ltd, Israel) thermal sensory testing device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alloknesis</measure>
    <time_frame>Change from baseline, up to three days after the first session</time_frame>
    <description>Alloknesis is measured by using mildly pruritic, non-painful von Frey nylon filaments of a predetermined intensity (generally 5-30 miliNewton of force).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mechanical Pain Thresholds and Sensitivity</measure>
    <time_frame>Change from baseline, up to three days after the first session</time_frame>
    <description>This test is performed using a pin-prick set (Aalborg University, Aalborg). The set consists of 8 needles each having a diameter of 0.6 mm and different force applications: 0.8, 1.6, 3.2, 6.4, 12.8, 25.6, 50.1 and 60.0 g</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain rating</measure>
    <time_frame>only on day 3 (third session)</time_frame>
    <description>The subject will rate the pain for 9 min by using a a visual analog scale (VAS) on a tablet. This scale goes from 0 to 100. 0 indicates 'no pain' and 100 indicates 'worst imaginable pain'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Itch rating</measure>
    <time_frame>only on day 3 (third session)</time_frame>
    <description>The subject will rate the itch for 9 min by using a a visual analog scale (VAS) on a tablet. This scale goes from 0 to 100. 0 indicates 'no itch' and 100 indicated 'worst imaginable itch'.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Lidocaine</condition>
  <condition>Itch</condition>
  <arm_group>
    <arm_group_label>EMLA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EMLA (lidocaine) +Itch (Histamine and cowhage)</intervention_name>
    <description>Cutaneous anaesthesia: will be topically induced by using EMLA cream 5%, a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark).&#xD;
Histamine: To deliver histamine, standard allergy skin prick test (SPT) lancets are applied.&#xD;
Cowhage: Cowhage spicules are 1-2 mm in length and have diameter of 1-3 um at their tip, once inserted into the epidermis, the spicules evoke a moderate sensation of itch and to a lesser extent sensations of burning and stinging pain.</description>
    <arm_group_label>EMLA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy men and women&#xD;
&#xD;
          -  18-60 years&#xD;
&#xD;
          -  Speak and understand English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Drug addiction defined as any use of cannabis, opioids or other drugs&#xD;
&#xD;
          -  Previous or current neurologic, musculoskeletal or mental illnesses&#xD;
&#xD;
          -  Lack of ability to cooperate&#xD;
&#xD;
          -  Current use of medications that may affect the trial&#xD;
&#xD;
          -  Skin diseases&#xD;
&#xD;
          -  Consumption of alcohol or painkillers 24 hours before the study days and between these&#xD;
&#xD;
          -  Acute or chronic pain&#xD;
&#xD;
          -  Participation in other trials within 1 week of study entry (4 weeks in the case of&#xD;
             pharmaceutical trials)&#xD;
&#xD;
          -  Known history of anaphylactic shock, or local allergy (contact dermatitis) to&#xD;
             lidocaine, prilocaine or other local anaesthetics of the amide type.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Lo Vecchio</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg University</name>
      <address>
        <city>Aalborg</city>
        <state>Nordjylland</state>
        <zip>92200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>January 13, 2021</last_update_submitted>
  <last_update_submitted_qc>January 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Silvia Lo Vecchio</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Histamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

